Use of Drifts and PLS for the Determination of Polymorphs of Piroxicam Alone and in Combination with Pharmaceutical Excipients: A Technical Note

Tantishaiyakul, Vimon; Permkam, Pattakarn; Suknuntha, Krit

doi:10.1208/s12249-007-9003-y

Cited by 11 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4. The FTIR spectra show prominent N-H stretching peaks for piroxicam froms I and II at 3,339 and 3,393 cm 1 , respectively (13,22). In addition, the FTIR spectra of cimetidine forms A and C display major peaks for C≡N stretching at 2,178 and 2,166 cm , respectively (18).…”

Section: Fourier Transform Infrared Spectroscopymentioning

confidence: 98%

Crystal Structure Transformations and Dissolution Studies of Cimetidine–Piroxicam Coprecipitates and Physical Mixtures

et al. 2009

Self Cite

View full text Add to dashboard Cite

Abstract. We have recently demonstrated that coprecipitation of cimetidine (C) and piroxicam (P) at a mole ratio of 1:1 results in the transformation of the crystalline forms of both drugs to an amorphous state. In this study, coprecipitates and physical mixtures of cimetidine and piroxicam were further investigated at C/P mole ratios of 1:10, 1:5, 1:4, 1:2, 10:1, 20:1, 30:1, 40:1, and 52.5:1, the latter being the composition of a clinically used dosage. The physicochemical properties of these samples were examined using X-ray diffraction and Fourier transform infrared spectroscopy. Additionally, dissolution of piroxicam in the samples at C/P mole ratios of 10:1, 20:1, 30:1, 40:1, and 52.5:1 was investigated at pH 1.2 and pH 4. In coprecipitates with C/P mole ratios of 10:1, 20:1, 30:1, and 40:1, crystalline forms of both drugs were transformed to amorphous states. A mixture of an amorphous state and cimetidine crystalline form A was observed for the coprecipitate with a C/P mole ratio of 52.5:1. For the coprecipitates with C/P mole ratios of 1:2, 1:4, 1:5, and 1:10, cimetidine form A was transformed to form C, whereas piroxicam form II was modified to form I. It is interesting that small molecules, instead of polymers or solvents, can cause such crystal structure transformations. The dissolution of piroxicam at pH 4 is lower than that at pH 1.2. Additionally, the coprecipitates and physical mixtures with C/P mole ratios of 10:1, 20:1, 30:1, 40:1, and 52.5:1 demonstrate substantially higher dissolution of piroxicam compared to that of drug alone.

show abstract

Section: Fourier Transform Infrared Spectroscopymentioning

confidence: 98%

Crystal Structure Transformations and Dissolution Studies of Cimetidine–Piroxicam Coprecipitates and Physical Mixtures

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

“…At present, both piroxicam forms, I and II, are commercially available in various countries. Of these two, form I, being more stable than the second form, is more extensively used to manufacture commercial capsules and tablets …”

Section: General Characteristicsmentioning

confidence: 99%

“…Eur.7.0) . Its aqueous solubility (without stating temperature) is 0.023 mg/mL . The equilibrium solubility of piroxicam at 37°C, determined by the shake‐flask method in McIlvaine buffer solutions at four pH levels (4.0, 5.0, 6.0, 7.0, and 7.8), was 0.0320, 0.0396, 0.198, 1.37, and 4.79 mg/mL, respectively .…”

Section: General Characteristicsmentioning

confidence: 99%

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Piroxicam

Шохин

Kulinich

Ramenskaya

et al. 2014

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…The 2008 literature also contained additional reports relating to investigations of the effects of secondary processing on phase composition, and aspects of these182–189 have been summarized in Table 4.…”

Section: Effects Associated With Secondary Processing Of Crystal Formsmentioning

confidence: 99%

Polymorphism Solvatomorphism 2008

Brittain¹

2010

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Use of Drifts and PLS for the Determination of Polymorphs of Piroxicam Alone and in Combination with Pharmaceutical Excipients: A Technical Note

Cited by 11 publications

References 21 publications

Crystal Structure Transformations and Dissolution Studies of Cimetidine–Piroxicam Coprecipitates and Physical Mixtures

Crystal Structure Transformations and Dissolution Studies of Cimetidine–Piroxicam Coprecipitates and Physical Mixtures

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Piroxicam

Polymorphism Solvatomorphism 2008

Contact Info

Product

Resources

About